Ligand Pharmaceuticals Incorporated Deal History & Licensing Activity
Ligand Pharmaceuticals Incorporated is a large biotech headquartered in US. Over the past three years, Ligand Pharmaceuticals Incorporated has been involved in 5 licensing and acquisition transactions, with a primary focus on Other (3 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Other
Focus Area
Ophthalmology
Ligand Pharmaceuticals Incorporated Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Ligand Pharmaceuticals Incorporated in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Ryjunea (royalty and milestone interest from Sydnexis-Santen license, EMEA) | Ligand Pharmaceuticals | Small Molecules | Approved | acquisition | Sep 15, 2026 |
| XOMA Royalty Corporation | Ligand Pharmaceuticals | Other | Approved | acquisition | Jul 14, 2026 |
Ligand Pharmaceuticals Incorporated Pipeline Focus
Therapeutic areas and modalities where Ligand Pharmaceuticals Incorporated is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Ligand Pharmaceuticals Incorporated's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Ophthalmology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Ophthalmology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for ophthalmology
Dermatology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for dermatology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Ligand Pharmaceuticals Incorporated Licensing & Deal Activity
Ligand Pharmaceuticals Incorporated is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, Ligand Pharmaceuticals Incorporated ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Ligand Pharmaceuticals Incorporated include Ophthalmology (2 deals and trials), Other (2 deals and trials), Dermatology (2 deals and trials), and Oncology (1 deal and trial). In terms of modality, Ligand Pharmaceuticals Incorporated has shown particular interest in other, small molecules, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Ligand Pharmaceuticals Incorporated and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Ligand Pharmaceuticals Incorporated's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.